News
Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation
Yuhan Corporation has in-licensed GI Innovation’s allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI
Yuhan Corporation to recoup KRW 200 billion investment in five years
Yuhan Corporation’s global R&D and open innovation strategy – in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that
Yuhan to invest 14% of its sales in R&D this year for “Lazertinib’s Phase-3 trial & Global Open Innovation
In 2020, Yuhan Corporation is going to invest the largest amount in history for its R&D program to speed up the development of Lazertinib (YH25448)
Yuhan USA’s 2019 Recap
With 2020 just around the corner, let’s take a look back at our 2019!It has been a wonderful year for us here at Yuhan USA